


# An Endothelial-to-Adipocyte Extracellular Vesicle Axis Governed by Metabolic State

## Graphical Abstract



## Authors

Clair Crewe, Nolwenn Joffin, Joseph M. Rutkowski, ..., Dwight A. Towler, Ruth Gordillo, Philipp E. Scherer

## Correspondence

philipp.scherer@utsouthwestern.edu

## In Brief

Extracellular vesicles exchange protein and lipid signals between endothelial cells and adipocytes conveying information about nutrient state changes from the blood in adipose tissues.

## Highlights

- A network of EV-mediated exchange of cellular material exists in adipose tissue
- This exchange can replace protein levels in adipocytes despite gene disruption
- EV trafficking in adipose tissue is regulated by the systemic metabolic state
- Endothelial cells pack extracellular molecules in EVs for release to adipose tissue



# An Endothelial-to-Adipocyte Extracellular Vesicle Axis Governed by Metabolic State

Clair Crewe,<sup>1</sup> Nolwenn Joffin,<sup>1</sup> Joseph M. Rutkowski,<sup>1</sup> Min Kim,<sup>1,2</sup> Fang Zhang,<sup>1,3</sup> Dwight A. Towler,<sup>4</sup> Ruth Gordillo,<sup>1</sup> and Philipp E. Scherer<sup>1,5,\*</sup>

<sup>1</sup>Touchstone Diabetes Center, Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, TX, USA

<sup>2</sup>Cardiovascular and Metabolic Disease Center (CMDC), Inje University, Busan, South Korea

<sup>3</sup>Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

<sup>4</sup>Department of Internal Medicine, Endocrine Division, the University of Texas Southwestern Medical Center, Dallas, TX, USA

<sup>5</sup>Lead Contact

\*Correspondence: [philipp.scherer@utsouthwestern.edu](mailto:philipp.scherer@utsouthwestern.edu)

<https://doi.org/10.1016/j.cell.2018.09.005>

## SUMMARY

We have uncovered the existence of extracellular vesicle (EV)-mediated signaling between cell types within the adipose tissue (AT) proper. This phenomenon became evident in our attempts at generating an adipocyte-specific knockout of caveolin 1 (cav1) protein. Although we effectively ablated the CAV1 gene in adipocytes, cav1 protein remained abundant. With the use of newly generated mouse models, we show that neighboring endothelial cells (ECs) transfer cav1-containing EVs to adipocytes *in vivo*, which reciprocate by releasing EVs to ECs. AT-derived EVs contain proteins and lipids capable of modulating cellular signaling pathways. Furthermore, this mechanism facilitates transfer of plasma constituents from ECs to the adipocyte. The transfer event is physiologically regulated by fasting/refeeding and obesity, suggesting EVs participate in the tissue response to changes in the systemic nutrient state. This work offers new insights into the complex signaling mechanisms that exist among adipocytes, stromal vascular cells, and, potentially, distal organs.

## INTRODUCTION

The communication between adipose tissue (AT) and other organs through secreted hormones is indispensable for the maintenance of systemic metabolic health (Crewe et al., 2017; Kusminski et al., 2016). Although extracellular vesicles (EV) are well established in oncology, studies have only recently recognized their important role in the organ-to-organ communication of metabolic signals (Thomou et al., 2017; Zhao et al., 2018). Several types of EVs exist, but, in the context of signaling, exosomes and microvesicles display marked potential (van Niel et al., 2018). Exosomes generally have the distinguishing features of a nano-size range (30–150 nm) and contain specific biochemical markers, such as the enrichment of tumor susceptibility gene 101 (TSG101) and ALG-2-interacting protein (ALIX) (Lötvall et al., 2014; Willms et al., 2016), and exosomes

are of endosomal origin. Microvesicles range in size from 50–1,000 nm and originate by budding of the plasma membrane (Kowal et al., 2016). Given the overlap in size and similarity in biochemical properties, it is often difficult to experimentally distinguish exosomes from small microvesicles (Kowal et al., 2016). Thus, the general term small EV (sEV) is often used to describe this highly heterogeneous population of EVs isolated by a 100,000 × *g* spin.

Many cell types secrete protein- and miRNA-rich sEVs that have intricate effects on recipient cells. sEVs produced by adipocytes induce an aggressive metabolic phenotype in melanoma cells, promote metastasis of lung cancer cells, and alter TGF- $\beta$  signaling in hepatocytes (Conlan et al., 2017; Koeck et al., 2014; Lazar et al., 2016). sEVs secreted from other cells in adipose tissue, such as macrophages or stem cells, can also have striking systemic effects when injected into mice, such as altering whole-body insulin sensitivity, glucose tolerance, and inflammation, which provides a new therapeutic avenue for the treatment of obesity and type 2 diabetes (Deng et al., 2009; Ying et al., 2017; Zhao et al., 2018). Although sEVs can be potentially engineered to provide a pharmacological payload, it is surprising that the most promising therapeutic application is through harnessing the characteristics of native EVs, complete with the cell-prepared cocktail of proteins, lipids, miRNAs, and cell-targeting mechanisms (Conlan et al., 2017).

These studies have laid an important foundation for our continued understanding of how cell-specific sEVs modulate whole-body metabolism. However, it is not clear whether tissue-derived EVs also participate in cell-to-cell communication within the tissue proper. In tumor microenvironment studies, EVs have emerged as an essential signaling mechanism between tumor cells and stromal cells to modulate proliferation, survival, and immunity (Lazar et al., 2016; Zhao et al., 2016). We provide evidence in this study that, in the context of metabolic regulation, sEVs mediate a form of cell-to-cell communication within adipose tissue, contributing to the multifaceted crosstalk between adipocytes and stromal vascular cells.

Here, we report the presence of a pool of EVs that reside in white adipose tissue and allow for a sizeable exchange of cellular material between cell types. This phenomenon became apparent in our adipocyte-specific caveolin 1 (cav1) knockout (KO) mouse model. Cav1 is an important membrane-bound



structural and signaling protein and is highly abundant in adipocytes and endothelial cells (ECs). Despite successful ablation of the *cav1* gene, the *cav1* protein remained readily detectable in adipocytes. This was found to be the result of sEV-mediated trafficking of *cav1* from neighboring ECs to the adipocytes. We used *cav1* as a marker for adipose tissue EVs and developed a novel mouse model of cell-specific miniSOG-tagged *cav1* overexpression. This model, combined with our cell-specific membrane-halo mouse, allowed us for the first time to track the movement of EVs between cell types *in vivo*. These adipose tissue sEVs are rich in protein and sphingolipids conferring a range of signaling capabilities. Here, we show that adipose tissue sEV production is increased in the fasted state, partially because of glucagon-stimulated sEV secretion from ECs. This response is absent in ECs isolated from mouse models of genetic and diet-induced obesity. Furthermore, we provide evidence that extracellular molecules are taken up by ECs and packaged into sEVs, marking a new mechanism by which blood-borne signals are integrated and supplied to adipose tissue. Overall, this EV-mediated signaling mechanism may be important for the appropriate response of adipose tissue to changes in systemic energy balance.

## RESULTS

### Adipocyte-Specific Elimination of *Cav1* *In Vivo*


The *cav1* gene was specifically ablated in mature adipocytes using the loxP system combined with either the constitutively expressed adiponectin-cre (aCre) or an adipocyte-specific TET-ON-inducible cre (iCre) transgene (Figures S1A and S1B). Gene ablation was confirmed in *in-vitro*-differentiated adipocytes expressing aCre by PCR amplification of the recombined allele (Figure 1A). In addition, immunofluorescent staining for *cav1* showed depletion of *cav1* protein in perilipin (PLIN)-positive differentiated adipocytes expressing aCre, although *cav1* was still detected in the surrounding stromal vascular cells (SVF; Figure 1B). A dramatic reduction in *cav1* mRNA was observed in mature adipocytes directly isolated and analyzed from the sWAT of mice expressing either cre system (Figures 1C and 1D). However, *in vivo*, *cav1* protein remained readily detectable in adipocytes isolated from sWAT in the inducible model, being reduced by just 40% (Figures 1E and 1G). Even in the model of constitutive cre expression, where *cav1* protein half-life is essentially irrelevant as the cre is active from birth, we observed only a 50%–60% reduction in *cav1* protein (Figures 1F and 1G). This is in contrast to our previously published work where we successfully depleted *cav1* protein in hepatocytes using the same floxed *cav1* mouse (Asterholm et al., 2012). These data raise the intriguing possibility that the *cav1* protein detected in these KO adipocytes was not endogenously produced, but instead originated from a source outside of the adipocyte. Intracellular localization of *cav1* provides further evidence. *Cav1* protein in aCre-expressing mice was still enriched at the plasma membrane in sWAT adipocytes, although at lower abundance than the control mice (Figure 1H). The greatest fold reduction in *cav1* content was found in the microsomal fraction corresponding to the processing of nascent *cav1* peptides in the ER and the vesicular trafficking of *cav1* between compartments (Figure 1H).

Although *cav1* was abundantly detected at the plasma membrane in aCre mice, characteristic flask-shaped caveolae were not formed (Figure 1I). These data suggest that, if there is an exogenous source of *cav1* protein, it does not localize and retain its function in the adipocyte as the endogenously produced protein.

### *Cav1* Is Trafficked from Endothelial Cells to Adipocytes *In Vitro* via EVs

To determine whether different cell types within the sWAT depot share membrane components, we transplanted sWAT pieces from mice in which all cells were constitutively labeled with membrane-bound red fluorescent protein (RFP) into the dorsal subcutaneous fat pad of mice, where only mature adipocytes were labeled with plasma membrane halo tag (Figures 2A and S2). The transplanted sWAT pieces were allowed to integrate into the host fat pad for 3 weeks. Both RFP and halo signals were detected in the same adipocytes at the site of transplantation, suggesting that adipocytes exchange membrane components with other cell types in the tissue (Figure 2B).

Previous studies have shown that *cav1* is secreted by select cell types and has been identified in the interstitial fluid of adipose tissue (Celis et al., 2005; Chang et al., 2017), establishing inter-cellular trafficking of *cav1* as a viable theory. However, exchange of *cav1* between cells has not been directly demonstrated. ECs are the most likely candidate for a potential source of external *cav1* transferred to adipocytes, as ECs have a pronounced presence in adipose tissue and highly express *cav1* protein (Lisanti et al., 1994). In support of this hypothesis, co-deletion of *cav1* from adipocytes and ECs *in vivo* using a combination of adiponectin-cre and VECAD-cre, respectively, resulted in efficient knockout of *cav1* protein in isolated adipocytes from the sWAT depot (Figures 2C, S1A, and S1C). We pursued further mechanistic evidence for this phenomenon of EC to adipocyte trafficking *in vitro*. The SVF fraction from the sWAT of whole-body *cav1* KO mice was differentiated into mature adipocytes and co-cultured with immortalized mouse ECs (bEnd.3), which have wild-type (WT) levels of *cav1* protein. The cells were fixed and stained for *cav1* and the adipocyte marker PLIN. *Cav1* signal was robustly detected in the adipocytes, suggesting that *cav1* can be trafficked from ECs to adipocytes *in vitro* (Figure 2D). This likely occurs through a vesicular mechanism, as *cav1* is a membrane-bound protein and most adipocytes in the co-culture are not in direct physical contact with an EC. WT ECs were co-cultured with *cav1* KO adipocytes in the presence of GW4869, an inhibitor of neutral sphingomyelinase (n-SMase) and commonly used to suppress exosome biogenesis. Despite its specificity, it may also inhibit the secretion of other types of EVs. GW4869 treatment resulted in diminished adipocyte *cav1* signal (Figure 2D). This suggests *cav1* can be transferred by an EV-based mechanism. Adipocytes also readily take up sEVs produced from primary adipose tissue ECs. Primary CD31<sup>+</sup> ECs were treated with fluorescein isothiocyanate-polyethylene glycol (FITC-PEG)-cholesterol to label the plasma membrane. ECs were then washed thoroughly to remove excess dye (Figure S3) and given fresh media for 2 days. Over this period, the ECs became completely depleted



**Figure 1. Efficient Depletion of Adipocyte Cav1 mRNA Results in a Partial Knockout of Cav1 Protein**

(A and B) SVF cells were isolated from sWAT of control or adiponectin promoter-cre (aCre)-expressing mice ( $n = 3$ ). SVF cells were differentiated and analyzed for cre-driven recombination (A) and stained for cav1 and the adipocyte marker perilipin (PLIN) (B).

(C–G) Adipocyte and SVF fractions from sWAT. Fractions from control (ctrl), adipocyte-specific-inducible cre (iCre; C) or adipocyte-specific constitutively active cre (aCre; D) were analyzed for cav1 mRNA ( $n = 3$ –4 mice per group; nd, not detected). Cav1 protein content was determined by WB analysis in fractions from iCre (E) or aCre (F) mice ( $n = 3$ –4 mice per group). (G) Representative WB images from isolated adipocytes from iCre, aCre, and whole-body cav1 knockout (CKO) mice. aCre mice were 15 weeks old and iCre mice were treated with doxycycline for three weeks.


(H) Mature adipocytes were isolated from the sWAT of control or aCre-expressing mice and fractionated into subcellular fractions: nucleus (nuc), mitochondria (mito), microsomes (micro), plasma membrane (PM), and cytoplasm (cyto). Control and aCre cav1 samples were run on the same gel, but the images were separated for easy comparison.

(I) Electron micrograph of control or aCre-expressing sWAT (representative of two mice per group). Arrows indicate examples of caveolar structures.

Data are presented as mean  $\pm$  SEM.

of FITC signal (Figure 2E). This corresponded with the appearance of FITC-labeled exosome-sized vesicles in the EC media as determined by nanoparticle tracking analysis (NTA; Figure 2F). Furthermore, isolated sEVs from EC-conditioned media (CM) contained cav1 protein (Figure 2H). This CM was then transferred to differentiated WT adipocytes and incubated under normal culture conditions for 6 hr. Adipocytes robustly took up

labeled EC sEVs resulting in a dramatic increase in adipocyte FITC signal (Figure 2G). These results, taken together, suggest that ECs secrete cav1-containing EVs that are taken up by neighboring adipocytes in culture. Although we focused on EC sEVs, cav1 also could be trafficked on other forms of EVs, such as larger microvesicles, a process we cannot formally exclude.



**Figure 2. Endothelial Cell-Derived Cav1 Is Transferred to Adipocytes In Vitro**

(A) Transplant schematic: pieces of sWAT from an MTMG mouse (where every cell is labeled with RFP) were implanted in the dorsal sWAT fat pad of a mouse expressing an adipocyte-specific halo tag at the plasma membrane.


(B) Confocal images of RFP and Halo in tissue sections ( $n = 3$  independent transplants). Arrows indicate examples of RFP and halo colocalization.

(C) Western blot densitometry and representative image of cav1 expression in isolated mature adipocytes from the sWAT of control or adipocyte and EC double cav1 KO mice ( $n = 3-4$ ).

(D) sWAT-derived SVF from whole-body cav1 KO mice was differentiated into adipocytes and co-cultured with bEND.3 ECs for 2 days  $\pm$  GW4869 (representative immunofluorescent confocal image of  $n = 3$ ).

(E-H) Primary CD31<sup>+</sup> EC were labeled with FITC-PEG-cholesterol to tag cell membranes ("FITC"), washed thoroughly, and given fresh media for 2 days ("FITC + 2d") (E). Appearance of FITC-labeled exosomal particles in the EC-conditioned media following 2-day incubation (F). WT differentiated adipocytes were

(legend continued on next page)



**Figure 3. Cav1 Is Trafficked from Endothelial Cells to Adipocytes In Vivo**

(A) Immunohistochemical analysis of the mini-SOG (mSOG)-tagged cav1 protein. Arrows indicate examples of positively stained vascular structures.

(B) Western blot analysis of miniSOG in purified SVF and adipocyte (Ad) fractions from sWAT.

(C) Western blot densitometry of the miniSOG tag in purified adipocyte fraction from the sWAT of mice with the specified diet relative. Mice were fed a high-fat diet (HFD) for 12 weeks. Data are presented as the ratio of adipocyte miniSOG to SVF miniSOG (n = 4). The western blot image is representative of an adipocyte mSOG signal over time.

(D) Immunohistochemistry for miniSOG and PLIN as detected by confocal microscopy (n = 4).

(E) The presence of cav1<sup>SOG</sup> in fluorescence-activated cell sorting (FACS)-sorted macrophages (MAC2), preadipocytes (PDGFRβ), and isolated adipocytes (APN) from sWAT.

(F) Western blot for CD31 in EC lysate and EC-derived sEVs.

(G and H) CD31 protein levels in SVF and adipocyte (Ad) fractions purified under fed or fasting conditions (G). Densitometry of CD31 protein levels and mRNA content in isolated adipocytes (n = 5–6) (H).

(I) Validation of adipocyte-specific membrane-halo mouse by western blot expression of the Halo tag in isolated mature adipocytes.

(J) Flow cytometric analysis of Halo tag in sWAT cell populations: preadipocytes (PDGFRβ), hematopoietic cells excluding macrophages (CD45), macrophages (mac), and ECs (n = 4). Data are presented as mean ± SEM.

See also Figures S4 and S5.

### Cav1 Is Trafficked from Endothelial Cells to Adipocytes In Vivo

To determine whether this trafficking event occurs *in vivo*, we generated a mouse that allows us to overexpress a mini-SOG-tagged cav1 fusion protein (cav1<sup>SOG</sup>; mini singlet oxygen generator) under the control of the TRE promoter in a TET-OFF system (Figure S1C). Using a VECAD-tTA transgene, we accomplished constitutive overexpression of cav1<sup>SOG</sup> specifically in ECs *in vivo*. In this way, we could track the movement of cav1 produced in ECs within the adipose tissue. We validated the newly generated anti-miniSOG antibody via western blot and immunofluorescence (IF) by demonstrating that cav1<sup>SOG</sup> was only detected in the mice carrying the TRE-cav1<sup>SOG</sup> transgene (Figures 3A and 3B). In addition, the miniSOG signal was identified in vascular structures (Figure 3A) and the EC-containing SVF of sWAT (Figure 3B). Remark-

ably, cav1<sup>SOG</sup> was also readily detected in the purified adipocyte fraction (Figure 3B). These data indicate that cav1<sup>SOG</sup> is transferred from ECs to adipocytes *in vivo*.

### Cav1 Transfer between Endothelial Cells and Adipocytes Is Regulated by Fasting and Feeding

To establish whether the transfer of cav1 to adipocytes is physiologically relevant, we monitored the behavior of this exchange under different physiological conditions. A major function of adipose tissue is to maintain systemic metabolic homeostasis despite dramatic changes in exogenous nutrient availability. Upon expressing cav1<sup>SOG</sup> in ECs, we found that the amount of cav1<sup>SOG</sup> that is trafficked from ECs to adipocytes is substantially increased in the fasted state and progressively returns to baseline levels when mice are re-fed for 3 and 6 hr (Figure 3C). We can also

treated with conditioned media from ECs alone (CM) with or ECs pretreated with FITC (CM + FITC) (G). sEVs were isolated from EC-conditioned media and analyzed by western blot for the presence of cav1 and the exosomal marker Alix, compared to whole-EC lysate (H).

All cell culture experiments are representative of three independent experiments. Data are presented as mean ± SEM.

See also Figure S3.

demonstrate this by IF, where, in the fasted state, considerably more cav1<sup>SOG</sup> was identified in the extracellular space and at the level of the adipocyte than in the fed state (Figure 3D). Upon re-feeding for 6 hr, the amount of cav1<sup>SOG</sup> detected in the interstitium and the adipocyte was similar to that observed in the fed state. In contrast, fasting-induced cav1<sup>SOG</sup> transfer to adipocytes is severely blunted in mice first fed a high-fat diet for 12 weeks (Figure 3C). These data suggest that the extent of cav1 trafficking is dictated by the metabolic requirements of the organism. Furthermore, cav1-containing EVs from ECs are likely targeted largely to adipocytes, compared to other cells in the adipose tissue, as cav1<sup>SOG</sup> was not detected in preadipocytes/mural cells and minimally detected in macrophages (Figure 3E).

Next, we determined whether cav1 was selectively transferred to adipocytes or whether other common plasma membrane proteins were also trafficked, as would be expected with an EV-based mechanism. Proteomics analysis of sEVs isolated from primary EC culture media identified CD31, an EC-enriched plasma membrane protein, as an abundant protein in sEVs compared to others like VE-cadherin. We confirmed the presence of CD31 in EC-derived sEVs by western blot (Figure 3F). Interestingly, per microgram of protein, EC-derived sEVs were highly enriched for CD31 compared to an EC cell lysate (Figure 3F). Furthermore, we detected CD31 in purified mature adipocytes from the SWAT and found that CD31 protein accumulated in adipocytes following a 16-hr fast (Figures 3G and 3H). This was not due to endogenous expression, as CD31 mRNA was almost undetectable in adipocytes and did not increase fasting (Figure 3H). Therefore, the trafficking of membrane bound proteins from ECs to adipocytes likely extends far beyond cav1. This “plasma membrane sharing” may explain why it has historically been challenging to find an adipocyte-specific plasma membrane marker.

As illustrated in Figure 3C, the influx of cav1<sup>SOG</sup> to the adipocyte is reversed upon re-feeding, indicating there is also a mechanism for the shedding of cav1 and other plasma membrane proteins from the adipocyte. To test this, we used the TRE-plasma membrane-halo mouse and inducibly labeled the adipocyte plasma membranes with a halo tag by treating mice with doxycycline for 2 weeks (Figure S2). As demonstrated in Figures 3I and S2, the halo tag is only expressed in the adipose tissue of mice carrying the transgene and specifically labeled adipocyte plasma membranes. Following the labeling period, the presence of the halo tag in other adipose tissue cells was assessed by Flow Cytometry using a fluorescent halo tag ligand (Figures S4 and S5). We found a striking 35% of the total EC population contained the halo tag (Figure 3J). In addition, other populations of SWAT SVF also contained the halo tag, such as macrophages, CD45<sup>+</sup> hematopoietic cells (excluding macrophages), and pdgfr $\beta$ <sup>+</sup> preadipocytes/mural cells (Figure 3J). The percentage of the macrophage population that was positive for halo was similar to that of ECs, whereas CD45<sup>+</sup> and pdgfr $\beta$ <sup>+</sup> cells contained less than 10% halo positive signal. These data suggest considerable membrane-based communication occurs between the adipocytes, ECs, and other SVF cells.

#### White Adipose Tissue Produces Cav1-Containing sEVs

Next, we pursued evidence for the presence of a tissue EV pool that may transport cav1, and other signaling molecules, between


cells in the adipose tissue. Immunofluorescent staining of WT adipose tissue revealed areas of the interstitial space that were positive for the exosomal marker CD63, which was not cell associated (DAPI stain; Figure 4A). Furthermore, mice overexpressing cav1<sup>SOG</sup> in ECs displayed the presence and co-localization of CD63 and cav1<sup>SOG</sup> in the intercellular space (Figure 4A). These data indicate that cav1<sup>SOG</sup> may be packaged into sEVs in ECs and transferred to neighboring adipocytes.

We developed a protocol to isolate sEV and large EV (lEV) fractions from white adipose tissue (Figure 4B). As illustrated in Figure 4C, the sEV fraction from SWAT equilibrated in a sucrose gradient at a density range constant with that published for exosomes (1.13–1.19 g/mL; F2-3) (Théry et al., 2006), but likely also contains other forms of sEVs. The sEV pellet contained proteins that are characteristic of exosomes, such as tetraspanins and ALIX, which have little to no presence at densities corresponding to endoplasmic reticulum microsomes (F4-5) and Golgi membranes (F1) (Figure 4C) (Théry et al., 2006). Cav1 was strongly detected only within the exosome-containing density range (Figure 4C). Furthermore, the sEV fraction was devoid of histone 3 and contained calreticulin at lower abundance than an SVF cell lysate (Figure 4D). These data suggest that the sEV pellet isolated from adipose tissue with this protocol contained little to no contamination with cellular debris. The lEV fraction contained a robust signal for cav1 (Figure S6A), suggesting this form of EV could participate in inter-cellular transfer of cav1. These EVs likely also contained apoptotic bodies, a type of EV that is rich in calreticulin and histones and floats at a density range of 1.16–1.28 g/mL (F4-5; Figure S6B) (Shin et al., 2017; Théry et al., 2009). Here, we focused our efforts mainly on characterizing the properties and signaling capacities of the sEV fraction.

The sEV fraction was enriched for established exosome proteins when compared to an SVF cell lysate, such as CD63, Alix, and TSG101 (Figure 4E). Other common exosomal proteins were identified by an unbiased mass spectrometry approach, such as the Flotillins and CD81 (Table S1). The presence of Cav1 was also identified in the adipose tissue sEVs by mass spectrometry (12 peptides, 61.8% coverage) and confirmed by western blot analysis (Figure 4E). Interestingly, among the two previously described cav1 isoforms ( $\alpha$  and  $\beta$ ), which arise from differential translational start sites at two distinct methionine residues 32 amino acids apart (Scherer et al., 1995), the  $\alpha$  isoform was selectively packaged into sEVs (Figure 4E) and is the form transferred to adipocytes (Figure 3B). This further underlines the highly selective enrichment process in tissue EVs. However, as previously mentioned, we do not believe the isoform that is transferred to adipocytes is fully functional with regards to forming caveolar structures (Figure 1I). By nanoparticle tracking analysis (NTA) and electron microscopy, we show that the isolated sEVs fall within the appropriate size distribution expected of a sEV/exosomal fraction (Figures 4F and 4G). These EVs were morphologically heterogeneous, although the majority exhibited a cup-like structure (Figure 4G).

#### Tissue sEVs Contain Proteins and Lipids with Signaling Potential

Serum EVs contain an array of proteins, metabolites, and RNA species that modulate signaling between various organs.



**Figure 4. Validation of Tissue sEV Isolation Protocol**

(A) Immunohistochemical staining for the exosomal marker CD63, the adipocyte maker PLIN, and miniSOG. Arrows indicate regions of extracellular CD63 staining (red) or CD63-mSOG colocalization (yellow) by confocal imaging.

(B) sWAT tissue sEV isolation schematic.

(C and D) Western blot of recovered proteins in a sucrose gradient for sEV markers (C) or non-sEV proteins (D).

(E) Western blot detection of cav1 or exosomal makers: CD63, Alix, and TSG101 in sWAT SVF or tissue sEV fractions.

(F) Nanoparticle tracking analysis (NTA) of purified sWAT tissue sEVs. The experiment was repeated three times.


(G) Transmission electron micrograph (TEM) of purified sWAT tissue sEVs.

See also [Figure S6](#) and [Table S1](#).

Likewise, identification of a tissue EV population has exciting implications for cell-cell signaling mechanisms within the adipose tissue itself. Proteomics analysis was employed to determine differences in sEV protein cargo as a function of fed/fast conditions. [Figure 5A](#) and [Table S2](#) illustrate the range of signaling pathways in adipose tissue sEVs that are enhanced from the fed to the fasted state. For example, proteins involved in Wnt and MAPK signaling were enriched during fasting. Other pathways significantly enriched in tissue sEVs during the fasted state included polyamine metabolism, antioxidant response, and transport of small molecules ([Figure 5A](#); [Table S2](#)). Interestingly,

mitochondrial respiratory chain components were also significantly represented in adipose tissue sEV under fasting conditions, a subcellular compartment generally considered to be excluded from exosomal cargo ([Lötvall et al., 2014](#)). In contrast, pathways significantly reduced in tissue sEVs isolated under fasting conditions included metabolism of lipids and metabolism of amino acids ([Figure 5B](#); [Table S3](#)).

In addition to signaling proteins, we determined whether these tissue sEVs contained a specific ceramide profile, as these lipid species have a well-documented spectrum of signaling capacities particularly in the context of stress. The shortest



**Figure 5. Tissue sEVs Contain Various Signaling Proteins and Lipids**

(A and B) Proteomics pathway analysis of sWAT tissue sEVs isolated from mice under fed or fasting conditions. Pathway analyses was conducted on the subset of proteins identified to be significantly higher (A) or lower (B) in the fasted versus fed states. (C–F) Quantification of ceramides (C), glycolceramides (D), So, Sa and S1P (E), and sphingomyelins (F) in adipose tissue ECs or adipose tissue sEVs (adipose tissue EVs were pooled from five mice for each condition;  $n = 3$ ).

So, sphingosine; Sa, sphinganine; S1P, sphingosine 1-phosphate. Data are presented as mean  $\pm$  SEM. See also Tables S2 and S3.

increased in the fasted state, suggesting an overall enhancement of sEV production and release (Figure 6B).

### Glucagon Enhances Adipose Tissue EC sEV Production through Ceramide Generation


The proteomics data showed a general trend toward an increase in EC-specific membrane markers identified in the tissue sEVs in the fasted state (data not shown), reflecting a greater contribution of ECs to the tissue sEV pool under fasting conditions.

chain length (C14 and C16), and the longest chain length ceramides (C26) were significantly lower in adipose tissue sEVs compared to whole-EC lysate (Figure 5C). In contrast, intermediate chain length ceramides (C18, C20, C22, and C24) were highly enriched in sEVs when compared to ECs (Figure 5C). Furthermore, hexosyl-ceramides were generally lower in tissue sEVs compared to the cell lysates, whereas lactosyl-ceramides were higher in the adipose tissue sEVs (Figure 5D). Lastly, adipose tissue sEVs displayed higher levels of sphinganine, sphingosine-1-phosphate (S1P) and all sphingomyelin species (Figures 5E and 5F). These data indicate that adipose tissue sEVs have a unique macromolecular composition with the potential to alter a wide range of signaling pathways within the tissue.

We directly tested whether  $cav1^{SOG}$  was transported in sEVs from ECs to adipocytes *in vivo*. Adipose tissue sEVs were isolated from mice overexpressing  $cav1^{SOG}$  in ECs and were analyzed for the presence of the miniSOG-tag in the fed and fasted states.  $Cav1^{SOG}$  was detected in adipose tissue sEVs, as was endogenous  $cav1$  (Figure 6A). Interestingly sEVs from fasting conditions contained less endogenous  $cav1$  but higher phospho- $cav1$  (Figure 6A). Thus, phospho- $cav1$  is enriched by 4.2-fold in sEVs. This suggests that a large fraction of  $cav1$  that enters sEVs is in an active signaling state, particularly under fasting conditions. The overall abundance of endogenous  $cav1$  or  $cav1^{SOG}$  in sEVs was not different under the fed relative to the fasted conditions and thus, cannot explain the observation that more  $cav1$  is trafficked to adipocytes in the fasted state. However, the total yield of sEVs from the tissue is significantly

increased in the fasted state, suggesting an overall enhancement of sEV production and release (Figure 6B). However, adipose tissue sEVs likely originate from multiple cell types. To better understand the specific communication between ECs and adipocytes in the fed and fasted states, we cultured primary AT ECs in the presence of either insulin (fed state) or a stabilized form of glucagon (acylated-glucagon; fasted state) for 2 days and quantified the sEVs released into the media. Insulin had no effect on sEV release; however, glucagon treatment resulted in a striking increase sEV production (Figure 6C). This effect was completely blocked by the addition GW4869 during the incubation (Figure 6C). We determined that glucagon selectively increased the release of sEV populations, but not IEVs, from primary ECs (Figure 6D). Interestingly, glucagon-stimulated sEV release was not observed in primary ECs isolated from lung tissue (Figure 6E), suggesting that this glucagon-mediated effect is not present in all CD31<sup>+</sup> cells. Rather, it is specific for ECs in adipose tissue.

It is well established that endosomal-derived exosome production and release is stimulated by n-SMase-dependent ceramide synthesis from sphingomyelin (Essandoh et al., 2015; Li et al., 2013b; Trajkovic et al., 2008). GW4869 is a potent inhibitor of neutral n-SMase. It therefore inhibits exosome production and may also affect secretion of other forms of sEVs because of the resultant alterations in cellular sphingolipid composition. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) lipidomics analysis revealed that glucagon stimulation of ECs resulted in a trend toward increased total cellular ceramide synthesis (Figure 6F), but significantly induced the production of glycosylated ceramides (Figure 6G) within 5 min of treatment. Hexosyl-ceramides displayed a particularly



**Figure 6. Glucagon Induces EC sEV Secretion**

(A) Mouse model of *cav1*<sup>SOG</sup> overexpression specifically in ECs. *Cav1*<sup>SOG</sup>, endogenous *cav1* and endogenous *p-cav1*<sup>Tyr14</sup> were detected by western blot in SVF and sEV fractions of sWAT tissue (representative of *n* = 4).

(B) adipose tissue sEV yield as determined by protein concentration in a fixed volume of re-suspended sEVs.

(C–E) Quantification of media EVs by NTA. The parent cells were ECs isolated from adipose tissue (C and D) or lung (E) treated with insulin (5 µg/mL) or acyl-glucagon (aGLN; 15 nM) as indicated. The sEV population was quantified in (C), whereas both sEVs (60–150 nm) and 1EVs (> 150 nm) were quantified in (D).

(F–K) Quantification of ceramides (F), glycol-ceramides (G), hexosyl-ceramide 20:0 (H), S1P (I), sphingomyelins (J) and dihydroceramides (K) by mass spectrometry in adipose tissue ECs during GLN stimulation (20 nM) at the time points shown (“cer” was used to abbreviate ceramides).

(L and M) Total ceramide (L) and sphingomyelin (M) content of ECs treated with acyl-glucagon (15 nM) for 2 days.

(legend continued on next page)

robust response to glucagon (Figure 6H). In addition, the well described signaling sphingolipid species (and product of ceramide degradation) S1P was also induced within 5 min of glucagon stimulation (Figure 6I). These data indicate that the ceramides produced in response to glucagon are also rapidly turned over. Consistent with a sMase-specific mechanism of rapid ceramide generation, the level of EC sphingomyelin species decreased over the 30 min time-course of glucagon treatment (Figure 6J). Interestingly, we also detected a significant drop in dihydroceramide C22:0 during a 5-min glucagon treatment (Figure 6K). This suggests some participation or compensation of the *de novo* ceramide biosynthetic pathway; however, based on experiments with GW4869, n-sMase is likely the major pathway for ceramide-induced sEV production in response to glucagon (Figure 6C). Treatment of ECs with acyl-glucagon for the time frame in which we harvest sEVs (2 day), did not result in high cellular ceramide levels (Figure 6L), a likely effect of high rates of ceramide turnover, although there was a significant depletion of sphingomyelins (Figure 6M).

Glucagon-mediated sEV production remained intact in ECs isolated from Cav1KO adipose tissue, suggesting Cav1 itself does not participate in this process (Figure 6N). Furthermore, glucagon did not enhance sEV secretion in ECs isolated from the adipose tissue of mice on a high-fat diet for 12 weeks compared to age-matched mice on a control diet (Figure 6O). Similarly, ECs from the adipose tissue of *ob/ob* mice, a genetic mouse model of obesity, displayed a severe defect in basal and glucagon-stimulated sEV production (Figure 6O). These differences in glucagon response could not be attributed to differential expression of the glucagon receptor as ECs from mice on a high-fat diet expressed *GCGR* to the same level as the control cells and those from *ob/ob* mice displayed higher *GCGR* expression (Figure 6P).

### Glucagon Signals to Enhance Extracellular Cargo Uptake and Packaging into sEVs

We have shown that glucagon increases sEV production from adipose tissue ECs. It is important to elucidate the physiological significance of this event. Proteomics analysis of cultured adipose tissue EC sEVs revealed the presence of a number of bovine serum proteins despite extensive washing of the sEV pellet to remove fetal bovine serum (FBS) components (Figure 7A). In fact, many FBS-derived bovine proteins were found to have abundance equal to or greater than the mouse proteins originating from the ECs themselves (Figure 7A). These data suggest that ECs engulf extracellular components, which are subsequently packaged into sEVs. Furthermore, there was some specificity to the media components that were incorporated into the sEVs, as bovine immunoglobulins were not detected in the sEV preparation. This is consistent with the major function of ECs, which is to relay messages from circulation to the underlying tissue, a process that is critical for metabolically important tissues, such as adipose tissue. ECs do this through well-defined path-

ways of transcytosis of soluble or albumin-bound nutrients and hormones. We tested whether BSA cargo is packaged into sEVs as a mechanism to transfer blood-borne signals to adipose tissue cells. Glucagon and, to a lesser extent insulin, significantly enhanced BSA uptake in primary adipose tissue ECs (Figures 7B and 7C). Overall BSA uptake was diminished in adipose tissue ECs isolated from *cav1*KO mice (Figure 7C), which is consistent with previous studies that report uptake of BSA-bound cargo is largely reliant on phosphorylation-dependent activation of *cav1* (Tyr<sup>14</sup>) (Li et al., 2013a; Zimnicka et al., 2016). However, the extent to which glucagon or insulin enhanced BSA uptake was unaffected by the absence of *cav1* (Figure 7C). Accordingly, glucagon treatment did not augment BSA-mediated phosphorylation of *cav1* (Figure 7D), compared to both C2 ceramide and H<sub>2</sub>O<sub>2</sub>, which were used as positive controls (Wehinger et al., 2015). These data suggest that insulin and glucagon enhance BSA uptake by a *cav1*-independent mechanism. It is likely occurring through an endocytosis or macropinocytosis-dependent mechanism (Li et al., 2013a). In addition, glucagon-induced BSA uptake and sEV production occur through distinct pathways, as GW4869 only suppressed sEV production (Figure 6C), but not BSA uptake (Figure 7E). Furthermore, basal BSA uptake was enhanced in adipose tissue ECs isolated from mice fed a high-fat diet for 12 weeks; however, no further stimulation of BSA uptake by glucagon was observed (Figure 7F). These data indicate dysregulation of this pathway by dietary nutrient excess.


We determined whether extracellular BSA taken up by ECs is packaged into sEVs, as observed with FBS-derived proteins (Figure 7A). Adipose tissue ECs were serum-starved for 4 hr, treated with normal BSA or biotinylated BSA for 30 min. Following BSA treatment, cells were washed thoroughly and provided with fresh media in the presence or absence of GW4869. After 2 days, sEVs from the media were isolated by ultracentrifugation and analyzed for the presence of biotin by SDS-PAGE and streptavidin reactivity. A 65kD biotinylated protein, corresponding to biotinylated BSA, was observed in the sEV prep (Figure 7G). Biotin incorporation into EVs was reduced with GW4869 treatment (Figure 7G), a reflection of overall suppression of sEV production. Taken together these results indicate that adipose tissue ECs take up extracellular molecules, which are packaged into sEV and secreted (Figure 7H).

## DISCUSSION

We have isolated and characterized a pool of adipose tissue-derived sEVs that traffic between cells within the tissue to communicate metabolic signals. Previous studies have suggested the existence of adipose tissue EVs, as adipose tissue interstitial fluid contains signaling proteins, such as those involved in the MAPK and nitric oxide pathways (Celis et al., 2005). Others have shown that cultured adipose tissue pieces secrete EVs (Deng et al., 2009). In this study, we have developed and refined

(N and O) NTA quantification of media EVs from adipose tissue ECs isolated from whole-body *cav1*KO mouse sWAT (N) or WT sWAT from mice under the indicated dietary conditions (O). Mice in the HFD condition were fed for 12 weeks before adipose tissue EC isolation.

(P) Glucagon receptor mRNA expression in culture primary adipose tissue ECs isolated from mice fed under the specified conditions. Data are presented as mean ± SEM.



**Figure 7. Glucagon Stimulates ECs to Take Up Extracellular Components, which Are Subsequently Incorporated into sEVs**

(A) *Mus musculus*- and *Bos taurus*-specific proteins identified by mass spectrometry in adipose tissue EC-derived sEVs.

(B and C) BSA-conjugated Alexa Fluor488 uptake assay was conducted on adipose tissue ECs stimulated with either insulin (5  $\mu$ g/mL) or glucagon (GLN; 10 nM). A representative fluorescence image following BSA-Alexa Fluor488 uptake (B). Quantification of Alexa Fluor488 intensity (n = 3–4) (C).

(D) Western blot densitometry of p-cav1<sup>Tyr14</sup> under the indicated conditions.

(E and F) BSA-Alexa Fluor488 uptake as described in (B) and in (C) with GW4869 treatment (E) or from ECs harvested from control or obese adipose tissue (F). ECs in (F) were isolated from mice on a chow or high-fat diet (HFD) for 12 weeks.

(G) ECs were treated with biotinylated BSA, washed and provided fresh media. Media sEVs were isolated, resuspended in a fixed volume, and analyzed for biotin BSA by SDS-PAGE and streptavidin-IRdye (SA-IRdye) reactivity.

(H) Model for the physiological significance of glucagon-stimulated BSA uptake and sEV production.

Data are presented as mean  $\pm$  SEM.

a protocol to isolate sEVs directly from adipose tissue *in vivo*, with minimal contamination by ruptured cells, and with sufficient yield for downstream applications. Initial proteomic characterization of these tissue sEVs has revealed that the protein profile is altered upon fasting (Figures 5A and 5B). Of particular interest, mitochondrial electron transport chain proteins were highly represented in tissue sEVs isolated under fasting conditions. Mitochondria are generally not considered a source for exosomal cargo (Lötvald et al., 2014). However, a recent study reported that mitochondrial fatty acid oxidation proteins were identified in sEVs secreted from cultured 3T3-F442A-differentiated adipocytes (Lazar et al., 2016), although the physiological relevance

of these findings *in vivo* were not clear. The incorporation of mitochondrial proteins into adipose tissue sEVs seems to be selective, as many electron transport chain proteins are significantly increased in the fasted state, whereas mitochondrial fatty acid oxidation proteins are decreased (Tables S2 and S3). We suspect that the ratio of mitochondrial components packaged into sEVs may affect the metabolic profile of recipient cells. In fact, we have strong evidence for such a mechanism in a transgenic model of altered mitochondrial function selectively in adipocytes (C.C. and C. Kusminski, unpublished data).

sEVs isolated from adipose tissue, were found to be enriched in sphingolipids, a class of lipids that have important signaling

and structural properties (Hla and Dannenberg, 2012). Depending on the species produced, ceramides can be potent second messengers for stress-related pathways (Ruvolo, 2001). This includes pathological signaling in the context of type 2 diabetes (Chavez and Summers, 2012). Enhanced integration of ceramides into tissue sEVs may reflect activation of nutrient stress responses in parent and recipient cells alike (Figure 5C). In addition, products of ceramide metabolism, hexosyl- and lactosyl-ceramides, also displayed differential enrichment in adipose tissue sEVs compared to total cellular content of these lipids. Hexosyl-ceramides were lower, and lactosyl-ceramides were higher in the sEV fraction compared to whole-cell lysates (Figure 5D). This is particularly interesting because these carbohydrate-ceramide derivatives act as precursors for the ganglioside family of lipids, which are highly abundant on the outer leaflet of the plasma membrane, and complex with cholesterol and sphingomyelin to form membrane microdomains (Krengel and Bousquet, 2014). A property of gangliosides that is potentially important for sEV biology is their role in cell-cell recognition and adhesion through the hydrophilic glycan head group, which can interact with proteins and other carbohydrate moieties on the surface of recipient cells (Krengel and Bousquet, 2014). Differential incorporation of glycosylated-ceramides into sEV membranes may target sEVs to specific cell types.

Although the tissue EV pool is likely the product of EV secretion from multiple cell types, including adipocytes and adipose tissue ECs, we focused here on EV-mediated communication between ECs and adipocytes. ECs constitute the interface between the plasma and the interstitial space where tissue cells reside. Bidirectional movement of nutrients and signaling molecules to and from interstitial fluid occur through well characterized mechanisms of EC transcytosis, including caveolae- and clathrin-mediated transcytosis, fused membrane channels or paracellular transport of small molecules (Simionescu et al., 2009; Tuma and Hubbard, 2003). Albumin, specifically and almost exclusively, traverses the endothelial membrane through caveolin-mediated transcytosis. Molecules that would otherwise have little to no solubility in plasma bind and travel with albumin into the tissue. These molecules include fatty acids, amino acids, hormones, xenobiotics, and cations. In keeping with previous reports, we have shown that cav1KO adipose tissue ECs display severe deficits in BSA uptake (Li et al., 2013a). However, glucagon- and insulin-stimulated BSA uptake is not dependent on cav1 (Figure 6C). Instead, this transport occurs through another pathway, likely a form of non-discriminant endocytosis of plasma components. Furthermore, BSA and bound cargo that is taken up by adipose tissue ECs is packaged into sEVs and secreted (Figures 7A and 7G). This process is accelerated by glucagon, which, as we report here, enhances sEV biogenesis. We propose that this process is a way for ECs to “sample” the plasma, integrate all blood-borne signals into a single package and deliver this “snapshot” of the systemic metabolic state to tissue cells. In particular, adipocytes seem to be the primary target cell for EC-derived sEVs (Figure 3E). This process relays more complex information than other forms of transcytosis, like information about the relative concentration of plasma components. Additionally, delivery of signals in this way would

facilitate synergistic activation of multiple cellular pathways, as all signals enter the cell in concert. Because EC sEVs contain extracellular/serum signaling molecules, we can speculate that the effect of EC sEVs on adipocyte physiology is dependent on the type of signals in the blood at any given time or condition. If so, it follows that EC sEVs would have the ability to customize the functional response of adipocytes to systemic changes in metabolism. Future work will be required to understand the potentially wide-ranging implications of the EC-adipocyte communication axis for adipocyte function and, consequently, whole-body metabolism.

Glucagon-stimulated EV secretion is not a phenomenon that occurs in all ECs. Instead, the presence of this mechanism is dependent on the tissue from which the ECs were isolated. ECs isolated from different tissues differ in morphology and functionality, a result of both genetic and environmental influences (Conway and Carmeliet, 2004; Craig et al., 1998). Adipose tissue ECs respond robustly to glucagon, whereas lung ECs do not (Figure 6E). This could be due to a number of differences, including the expression of the glucagon receptor or downstream signaling components like sMase. ECs in adipose tissue are essential for the integration and coordination of adipose tissue function with system-wide metabolic demands, which requires the movement of innumerable signaling molecules in and out of the tissue. In contrast, although transcytosis in lung ECs is also important, the major function of lung capillaries is to facilitate the diffusion of oxygen and CO<sub>2</sub> molecules to and from circulation. These functional differences provide a physiological explanation for the divergent responses of adipose tissue and lung ECs observed in this study.

The discovery and characterization of circulating EVs such as microvesicles and exosomes has offered remarkable insight into inter-organ communication, and the therapeutic potential of targeting these EVs. Likewise, understanding the role that EVs may play in cell-to-cell communication within a given tissue microenvironment may be just as fruitful, particularly for those tissues where the local interaction of tissue cells can have a dramatic effect on whole-body metabolic homeostasis. A prominent example of this is white adipose tissue, where an appropriate, coordinated response of adipocytes, ECs, immune cells, and fibroblasts is required to expand or contract the fat pad depending on nutrient availability (Crewe et al., 2017). The efficiency at which adipose tissue completes this task directly reflects the difference between systemic metabolic health and pathological responses. Further efforts to understand tissue EV biology will aid in development of novel therapies with broad applications for the treatment of diabetes.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mouse Models
  - bEND.3 Cell Line

- Stromal Vascular Cells and Adipocyte Differentiation
- Primary Adipose Tissue Endothelial Cells
- **METHOD DETAILS**
  - Isolation of Primary Adipocytes, Stromal Vascular Cells and Endothelial Cells
  - Adipocyte Subcellular Fractionation
  - Flow Cytometry
  - Flow Cytometry Gating Strategy
  - Cell Labeling Techniques
  - BSA-Alexa Fluor 488 and Biotin-BSA Uptake Assay
  - Transplant Studies
  - Immunofluorescence
  - Isolation of sEVs from Adipose Tissue
  - Isolation of sEVs From Cell Culture Conditioned Media
  - Nanoparticle Tracking Analysis
  - Proteomics and Pathway Analysis
  - Sucrose Gradient Fractionation Analysis of EVs
  - Sphingolipid Quantification
  - Western Blot
  - Transmission Electron Microscopy
  - qPCR
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

## SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and three tables and can be found with this article online at <https://doi.org/10.1016/j.cell.2018.09.005>.

## ACKNOWLEDGMENTS

We thank the following UT Southwestern Core Units: Histology Core for assistance in embedding and processing of tissue samples, the Metabolic Core for sphingolipidomics, the Proteomics Core for protein identification, and the Transgenic Core for their help in generating mice. This study was supported by U.S. NIH grants (R01-DK55758, P01-DK088761, R01-DK099110, and P01-AG051459) and by an unrestricted grant from the Novo Nordisk Research Foundation (to P.E.S.). C.C. is supported by NIH grant F32-DK113704.

## AUTHOR CONTRIBUTIONS

C.C., J.M.R., and P.E.S. conceptualized the project. C.C. and P.E.S. wrote the manuscript. C.C. and P.E.S. designed the experiments and C.C. conducted the experiments. N.J. performed the FACS and the flow cytometry experiments. F.Z. assisted in mouse experiments. J.M.R. and M.K. produced and validated mouse lines. R.G. conducted all sphingolipid analyses. D.A.T. provided resources.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: March 30, 2018

Revised: July 2, 2018

Accepted: September 4, 2018

Published: October 4, 2018

## REFERENCES

Asterholm, I.W., Mundy, D.I., Weng, J., Anderson, R.G., and Scherer, P.E. (2012). Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. *Cell Metab.* 15, 171–185.

Celis, J.E., Moreira, J.M., Cabezon, T., Gromov, P., Friis, E., Rank, F., and Gromova, I. (2005). Identification of extracellular and intracellular signaling

components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. *Mol. Cell. Proteomics* 4, 492–522.

Chang, C.C., Chen, C.Y., Wen, H.C., Huang, C.Y., Hung, M.S., Lu, H.C., Chen, W.L., and Chang, C.H. (2017). Caveolin-1 secreted from adipose tissues and adipocytes functions as an adipogenesis enhancer. *Obesity (Silver Spring)* 25, 1932–1940.

Chavez, J.A., and Summers, S.A. (2012). A ceramide-centric view of insulin resistance. *Cell Metab.* 15, 585–594.

Chiou, N.-T., and Ansel, K.M. (2016). Improved exosome isolation by sucrose gradient fractionation of ultracentrifuged crude exosome pellets. *Protoc. Exch.* <https://doi.org/10.1038/protex.2016.057>.

Conlan, R.S., Pisano, S., Oliveira, M.I., Ferrari, M., and Mendes Pinto, I. (2017). Exosomes as Reconfigurable Therapeutic Systems. *Trends Mol. Med.* 23, 636–650.

Conway, E.M., and Carmeliet, P. (2004). The diversity of endothelial cells: a challenge for therapeutic angiogenesis. *Genome Biol.* 5, 207.

Craig, L.E., Spelman, J.P., Strandberg, J.D., and Zink, M.C. (1998). Endothelial cells from diverse tissues exhibit differences in growth and morphology. *Microvasc. Res.* 55, 65–76.

Crewe, C., An, Y.A., and Scherer, P.E. (2017). The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. *J. Clin. Invest.* 127, 74–82.

Deng, Z.B., Poliakov, A., Hardy, R.W., Clements, R., Liu, C., Liu, Y., Wang, J., Xiang, X., Zhang, S., Zhuang, X., et al. (2009). Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. *Diabetes* 58, 2498–2505.

Essandoh, K., Yang, L., Wang, X., Huang, W., Qin, D., Hao, J., Wang, Y., Zingarelli, B., Peng, T., and Fan, G.C. (2015). Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. *Biochim. Biophys. Acta* 1852, 2362–2371.

Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016). The Reactome pathway Knowledgebase. *Nucleic Acids Res.* 44 (D1), D481–D487.

Hla, T., and Dannenberg, A.J. (2012). Sphingolipid signaling in metabolic disorders. *Cell Metab.* 16, 420–434.

Kalantari, R., Hicks, J.A., Li, L., Gagnon, K.T., Sridhara, V., Lemoff, A., Mirzaei, H., and Corey, D.R. (2016). Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells. *RNA* 22, 1085–1098.

Koeck, E.S., Iordanskaia, T., Sevilla, S., Ferrante, S.C., Hubal, M.J., Freishtat, R.J., and Nadler, E.P. (2014). Adipocyte exosomes induce transforming growth factor beta pathway dysregulation in hepatocytes: a novel paradigm for obesity-related liver disease. *J. Surg. Res.* 192, 268–275.

Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J.P., Prindal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., and Théry, C. (2016). Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc. Natl. Acad. Sci. USA* 113, E968–E977.

Krengel, U., and Bousquet, P.A. (2014). Molecular recognition of gangliosides and their potential for cancer immunotherapies. *Front. Immunol.* 5, 325.

Kusminski, C.M., Bickel, P.E., and Scherer, P.E. (2016). Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nat. Rev. Drug Discov.* 15, 639–660.

Lazar, I., Clement, E., Dauvillier, S., Milhas, D., Ducoux-Petit, M., LeGonidec, S., Moro, C., Soldan, V., Dalle, S., Balor, S., et al. (2016). Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer. *Cancer Res.* 76, 4051–4057.

Li, H.H., Li, J., Wasserloos, K.J., Wallace, C., Sullivan, M.G., Bauer, P.M., Stolz, D.B., Lee, J.S., Watkins, S.C., St Croix, C.M., et al. (2013a). Caveolae-dependent and -independent uptake of albumin in cultured rodent pulmonary endothelial cells. *PLoS ONE* 8, e81903.

- Li, J., Liu, K., Liu, Y., Xu, Y., Zhang, F., Yang, H., Liu, J., Pan, T., Chen, J., Wu, M., et al. (2013b). Exosomes mediate the cell-to-cell transmission of IFN- $\alpha$ -induced antiviral activity. *Nat. Immunol.* **14**, 793–803.
- Lisanti, M.P., Scherer, P.E., Vidugiriene, J., Tang, Z., Hermanowski-Vosatka, A., Tu, Y.H., Cook, R.F., and Sargiacomo, M. (1994). Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. *J. Cell Biol.* **126**, 111–126.
- Lötvall, J., Hill, A.F., Hochberg, F., Buzás, E.I., Di Vizio, D., Gardiner, C., Gho, Y.S., Kurochkin, I.V., Mathivanan, S., Quesenberry, P., et al. (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J. Extracell. Vesicles* **3**, 26913.
- Ruvolo, P.P. (2001). Ceramide regulates cellular homeostasis via diverse stress signaling pathways. *Leukemia* **15**, 1153–1160.
- Scherer, P.E., Tang, Z., Chun, M., Sargiacomo, M., Lodish, H.F., and Lisanti, M.P. (1995). Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe. *J. Biol. Chem.* **270**, 16395–16401.
- Shin, S., Han, D., Park, M.C., Mun, J.Y., Choi, J., Chun, H., Kim, S., and Hong, J.W. (2017). Separation of extracellular nanovesicles and apoptotic bodies from cancer cell culture broth using tunable microfluidic systems. *Sci. Rep.* **7**, 9907.
- Simionescu, M., Popov, D., and Sima, A. (2009). Endothelial transcytosis in health and disease. *Cell Tissue Res.* **335**, 27–40.
- Thery, C., Amigorena, S., Raposo, G., and Clayton, A. (2006). Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr. Protoc. Cell Biol. Chapter 3*, Unit 3.22.
- Théry, C., Ostrowski, M., and Segura, E. (2009). Membrane vesicles as conveyors of immune responses. *Nat. Rev. Immunol.* **9**, 581–593.
- Thomou, T., Mori, M.A., Dreyfuss, J.M., Konishi, M., Sakaguchi, M., Wolfrum, C., Rao, T.N., Winnay, J.N., Garcia-Martin, R., Grinspoon, S.K., et al. (2017). Adipose-derived circulating miRNAs regulate gene expression in other tissues. *Nature* **542**, 450–455.
- Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwill, P., Brügger, B., and Simons, M. (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science* **319**, 1244–1247.
- Tuma, P., and Hubbard, A.L. (2003). Transcytosis: crossing cellular barriers. *Physiol. Rev.* **83**, 871–932.
- van Niel, G., D'Angelo, G., and Raposo, G. (2018). Shedding light on the cell biology of extracellular vesicles. *Nat. Rev. Mol. Cell Biol.* **19**, 213–228.
- Wang, Z.V., Deng, Y., Wang, Q.A., Sun, K., and Scherer, P.E. (2010). Identification and characterization of a promoter cassette conferring adipocyte-specific gene expression. *Endocrinology* **151**, 2933–2939.
- Wehinger, S., Ortiz, R., Diaz, M.I., Aguirre, A., Valenzuela, M., Llanos, P., McMaster, C., Leyton, L., and Quest, A.F. (2015). Phosphorylation of caveolin-1 on tyrosine-14 induced by ROS enhances palmitate-induced death of beta-pancreatic cells. *Biochim. Biophys. Acta* **1852**, 693–708.
- Willms, E., Johansson, H.J., Mäger, I., Lee, Y., Blomberg, K.E., Sadik, M., Alaarg, A., Smith, C.I., Lehtiö, J., El Andaloussi, S., et al. (2016). Cells release subpopulations of exosomes with distinct molecular and biological properties. *Sci. Rep.* **6**, 22519.
- Ying, W., Riopel, M., Bandyopadhyay, G., Dong, Y., Birmingham, A., Seo, J.B., Ofrecio, J.M., Wollam, J., Hernandez-Carretero, A., Fu, W., et al. (2017). Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. *Cell* **171**, 372–384.e12.
- Zhao, H., Yang, L., Baddour, J., Achreja, A., Bernard, V., Moss, T., Marini, J.C., Tudawe, T., Seviour, E.G., San Lucas, F.A., et al. (2016). Tumor micro-environment derived exosomes pleiotropically modulate cancer cell metabolism. *eLife* **5**, e10250.
- Zhao, H., Shang, Q., Pan, Z., Bai, Y., Li, Z., Zhang, H., Zhang, Q., Guo, C., Zhang, L., and Wang, Q. (2018). Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and beiging in white adipose tissue. *Diabetes* **67**, 235–247.
- Zimnicka, A.M., Husain, Y.S., Shajahan, A.N., Sverdlov, M., Chaga, O., Chen, Z., Toth, P.T., Klomp, J., Karginov, A.V., Tirupathi, C., et al. (2016). Src-dependent phosphorylation of caveolin-1 Tyr-14 promotes swelling and release of caveolae. *Mol. Biol. Cell* **27**, 2090–2106.

## STAR★METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE                                  | SOURCE                     | IDENTIFIER                         |
|------------------------------------------------------|----------------------------|------------------------------------|
| <b>Antibodies</b>                                    |                            |                                    |
| Adiponectin                                          | Covance, rabbit anti-serum | N/A                                |
| Alix                                                 | Santa Cruz                 | Cat#: 53540; RRID: AB_673819       |
| CALR                                                 | Cell Signaling Technology  | Cat#: 12238; RRID: AB_2688013      |
| Cav1                                                 | Cell Signaling Technology  | Cat#: 3267; RRID: AB_2275453       |
| Beta tubulin                                         | Abcam                      | Cat#: ab6046; RRID: AB_2210370     |
| CD9                                                  | BD Biosciences             | Cat#: 553758; RRID: AB_395032      |
| CD31 for Western Blot                                | Cell Signaling Technology  | Cat#: 77699; RRID: AB_2722705      |
| CD31 for primary endothelial cell sorting            | BD Biosciences             | Cat#: 553370; RRID: AB_394816      |
| CD63                                                 | Santa Cruz                 | Cat#: 5275; RRID: AB_627877        |
| COXIV                                                | Abcam                      | Cat#: ab14744; RRID: AB_301443     |
| GAPDH                                                | Cell Signaling Technology  | Cat#: 2118; RRID: AB_561053        |
| Halo                                                 | Promega                    | Cat#: G9281; RRID: AB_713650       |
| H3                                                   | Cell Signaling Technology  | Cat#: 4499; RRID: AB_10544537      |
| MAC2 (Galectin-3) Clone M3/38                        | BioLegend                  | Cat#: 125401; RRID: AB_1134237     |
| miniSOG                                              | Covance, rabbit anti-serum | N/A                                |
| pCav1 Tyr14                                          | Cell Signaling Technology  | Cat#: 3251; RRID: AB_2244199       |
| PDGFR $\beta$                                        | Santa Cruz                 | Cat#: sc-432; RRID: AB_631068      |
| Perilipin                                            | Fitzgerald                 | Cat#: 20R-PP004; RRID: AB_1288416  |
| RFP (Biotin)                                         | Abcam                      | Cat#: ab34771; RRID: AB_777699     |
| SMA                                                  | Abcam                      | Cat#: 5694; RRID: AB_2223021       |
| TSG101                                               | Santa Cruz                 | Cat#: 7964; RRID: AB_671392        |
| VECAD                                                | Abcam                      | Cat#: ab33168; RRID: AB_870662     |
| Donkey anti-rabbit IRDye 680RD                       | Li-Cor                     | Cat#: 926-68073; RRID: AB_10954442 |
| Donkey anti-mouse IRDye 680RD                        | Li-Cor                     | Cat#: 926-68072; RRID: AB_10953628 |
| Goat anti-rat IRDye 680RD                            | Li-Cor                     | Cat#: 925-68076; RRID: AB_10956590 |
| Goat anti-rabbit IRDye 800CW                         | Li-Cor                     | Cat#: 925-32211; RRID: AB_2651127  |
| Goat anti-mouse IRDye 800CW                          | Li-Cor                     | Cat#: 926-32210; RRID: AB_621842   |
| Chicken anti-mouse Alexa Fluor 594                   | Invitrogen                 | Cat#: A-21201; RRID: AB_141630     |
| Goat anti-guinea pig Alexa Fluor 647                 | Invitrogen                 | Cat#: A-21450; RRID: AB_141882     |
| Goat anti-rabbit Alexa Fluor 488                     | Invitrogen                 | Cat#: A-11008; RRID: AB_143165     |
| APC Anti-CD140b clone APB5                           | BioLegend                  | Cat#: 136008; RRID: AB_2268091     |
| BB700 Anti-CD11b clone M1/70                         | BD Biosciences             | Cat#: 566417; RRID: AB_2744272     |
| BV421 Anti-CD45 clone 30-F11                         | BD Biosciences             | Cat#: 563890; RRID: AB_2651151     |
| FITC Anti-CD31 clone 390                             | BD Biosciences             | Cat#: 558738; RRID: AB_397097      |
| PECF594 Anti-F4/80 clone T45-2342                    | BD Biosciences             | Cat#: 565613; RRID: AB_2734770     |
| <b>Chemicals, Peptides, and Recombinant Proteins</b> |                            |                                    |
| 3-isobutyl-1-methylxanthine (IBMX)                   | Sigma                      | Cat#: I7018                        |
| Amicon Ultra-15 centrifugal filter units (100KD)     | Millipore                  | Cat#: UFC910024                    |
| BSA (Fatty acid free, low endotoxin)                 | Sigma                      | Cat#: A8806                        |
| BSA (Alexa Fluor <sup>488</sup> - Conjugated)        | ThermoFisher               | Cat#: A13100                       |
| CaCl <sub>2</sub>                                    | Sigma                      | Cat#: C7902                        |
| Collagenase D                                        | Roche                      | Cat#: 11088882001                  |
| Collagenase Type I                                   | Worthington                | Cat#: X7H9763A                     |
| C2-Ceramide                                          | Enzo                       | Cat#: BML-SL100-0005               |

(Continued on next page)

**Continued**

| REAGENT or RESOURCE                             | SOURCE                                                  | IDENTIFIER            |
|-------------------------------------------------|---------------------------------------------------------|-----------------------|
| Dapi                                            | Sigma                                                   | Cat#: D9542           |
| Dexamethasone                                   | Sigma                                                   | Cat#: D4902           |
| Dispase II                                      | Roche                                                   | Cat#: 04942078001     |
| DMEM high glucose                               | ThermoFisher                                            | Cat#: 11965092        |
| DMEM F12 with GlutaMAX                          | ThermoFisher                                            | Cat#: 10565-042       |
| Doxycycline diet                                | Bio Serve                                               | Cat#: S4107           |
| Dynabeads                                       | Invitrogen                                              | Cat#: 110.35          |
| EDTA                                            | ChemCruz                                                | Cat#: Sc-203932       |
| EGTA                                            | Sigma                                                   | Cat#: E3889           |
| Endothelial Cell Growth Supplement (ECGS)       | Alfa Aesar                                              | Cat#: J64516          |
| EZ-Link NHS-Biotin                              | ThermoFisher                                            | Cat#: 20217           |
| Fc Block                                        | BD Biosciences                                          | Cat#: 553142          |
| Fetal Bovine Serum (FBS)                        | Fisher Scientific                                       | Cat#: 03-600-511      |
| Fetal Bovine Serum (FBS) Exosome-Free           | System Biosciences                                      | Cat#: EXO-FBSHI-50A-1 |
| FITC-PEG-Cholesterol                            | Nanocs                                                  | Cat#: PG2-CSFC-5k     |
| Gelatin (2%)                                    | Sigma                                                   | Cat#: G1393           |
| Gentamycin                                      | GIBCO                                                   | Cat#: 15750-060       |
| Glucagon                                        | Sigma                                                   | Cat#: G2044           |
| Glucagon (Acylated)                             | A generous gift from William Holland (Utah)             | N/A                   |
| Glucose                                         | GIBCO                                                   | Cat#: 15023-021       |
| GW4869                                          | Sigma                                                   | Cat#: 567715          |
| Halo Tag TMRDirect                              | Promega                                                 | Cat#: G299A           |
| HEPES                                           | GIBCO                                                   | Cat#: 15630-080       |
| Insulin                                         | Sigma                                                   | Cat#: I6634           |
| IRDye 800CW Streptavidin                        | Li-COR                                                  | Cat#: 926-32230       |
| iScript cDNA Synthesis Kit                      | BIORAD                                                  | Cat#: 1708890         |
| NaF                                             | Sigma                                                   | Cat#: S6776           |
| Na <sub>3</sub> VO <sub>4</sub> (Orthovanadate) | Sigma                                                   | Cat#: S6508           |
| NTA 488nm Fluorescence Standard Beads           | Malvern                                                 | Cat#: NTA4095         |
| NuPAGE 4-12% Bis-Tris Gel                       | ThermoFisher                                            | Cat#: NP0335BOX       |
| MatTek Glass Bottom Microwell Dishes            | MatTek                                                  | Cat#: P35G-1.5-10-C   |
| MgCl <sub>2</sub>                               | Fisher Scientific                                       | Cat#: M35-500         |
| Penicillin-Streptomycin (10, 000U/mL)           | ThermoFisher                                            | Cat#: 15140122        |
| Sucrose                                         | Fisher Scientific                                       | Cat#: BP220-212       |
| SYBR Green PCR Master Mix                       | Applied Biosystems                                      | Cat#: 4309155         |
| Syringe-driven filter (0.22 μm)                 | Millipore                                               | Cat#: SLGP033NS       |
| Trehalose                                       | Sigma                                                   | Cat#: T0167           |
| Triton X-100                                    | Sigma                                                   | Cat#: T9284           |
| TRIzol reagent                                  | Fisher Scientific                                       | Cat#: 12034977        |
| Red Blood Cell Lysis Buffer                     | Sigma                                                   | Cat#: R7757           |
| Rosiglitazone                                   | Sigma                                                   | Cat#: R2408           |
| Experimental Models: Cell Lines                 |                                                         |                       |
| bEND.3 Cells                                    | A generous gift from Michael Dellinger, UT Southwestern | N/A                   |
| Experimental Models: Organisms/Strains          |                                                         |                       |
| mouse: B6;FVB-Tg floxed cav1                    | <a href="#">Asterholm et al., 2012</a>                  | N/A                   |
| mouse: B6-Tg Membrane halo                      | This paper                                              | N/A                   |

(Continued on next page)

**Continued**

| REAGENT or RESOURCE                                                           | SOURCE                                | IDENTIFIER                                                          |
|-------------------------------------------------------------------------------|---------------------------------------|---------------------------------------------------------------------|
| mouse: B6-Tg TRE-miniSOG                                                      | This paper                            | N/A                                                                 |
| mouse: B6-Tg adiponectinP-rtTA                                                | <a href="#">Wang et al., 2010</a>     | N/A                                                                 |
| mouse: Cav1 <sup>tm1Mls</sup> /J (Cav1 KO)                                    | Jackson Laboratory                    | No. 004585                                                          |
| mouse: B6.Cg-Tg(tet0-cre)1Jaw/J                                               | Jackson Laboratory                    | No. 006234                                                          |
| mouse: B6;FVB-Tg (Adipoq-cre)1Evdr/J                                          | Jackson Laboratory                    | No. 028020                                                          |
| mouse: WT C57BL6/J                                                            | Jackson Laboratory                    | No. 000664                                                          |
| mouse: B6. FVB-Tg (Cdh5-cre)7Mlia/J (VECAD-cre)                               | Jackson Laboratory                    | No. 006137                                                          |
| mouse: FVB-Tg (Cdh5-tTA) D5Lbjn/J (VECAD-tTA)                                 | Jackson Laboratory                    | No.013585                                                           |
| Oligonucleotides                                                              |                                       |                                                                     |
| <i>Mus</i> Cav1 qPCR Forward Primer: 5'-ATGTCTGGGGGC AAATACGTG-3              | Sigma                                 | N/A                                                                 |
| <i>Mus</i> Cav1 qPCR Reverse Primer: 5'-CGCGTCATACA CTTGCTTCT-3               | Sigma                                 | N/A                                                                 |
| <i>Mus</i> GgR qPCR Forward Primer: 5'-CCGAAA CTACATCCATGGGAACCTGT-3          | Sigma                                 | N/A                                                                 |
| <i>Mus</i> GgR qPCR Reverse Primer: 5'-ATCTTCTG GCTGTACCGTGTCTTCAG-3'         | Sigma                                 | N/A                                                                 |
| beta-2-microglobulin (B2M) qPCR Forward Primer: 5'-TTCTGGTGCTTGCTCACTGA-3'    | Sigma                                 | N/A                                                                 |
| beta-2-microglobulin (B2M) qPCR Reverse Primer: 5'-CAGTATGTTTCGGCTTCCCATTC-3' | Sigma                                 | N/A                                                                 |
| Recombinant DNA                                                               |                                       |                                                                     |
| pDisplay-Halo vector                                                          | ThermoFisher                          | V66020                                                              |
| pBAD vector                                                                   | A kind gift from Roger Tsien)         | N/A                                                                 |
| pTRE-promoter vector                                                          | Clontech                              | Cat#: 631059                                                        |
| Software and Algorithms                                                       |                                       |                                                                     |
| Excel                                                                         | Microsoft                             | N/A                                                                 |
| Fiji (ImageJ)                                                                 | Fiji                                  | <a href="https://fiji.sc/">https://fiji.sc/</a>                     |
| FlowJo                                                                        | FlowJo                                | <a href="https://www.flowjo.com/">https://www.flowjo.com/</a>       |
| ImageJ                                                                        | NIH                                   | <a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a> |
| LabSolutions V 5.82                                                           | Shimadzu Scientific Instruments       | N/A                                                                 |
| LabSolutions Insight V 2.0 program packages                                   | Shimadzu Scientific Instruments       | N/A                                                                 |
| Prism                                                                         | GraphPad Software                     | GraphPad Software                                                   |
| Reactome                                                                      | <a href="#">Fabregat et al., 2016</a> | N/A                                                                 |
| Other                                                                         |                                       |                                                                     |
| Zeiss LSM8800 Airyscan Confocal Microscope                                    | Zeiss                                 | N/A                                                                 |
| Keyence BZ-X700 Fluorescence Microscope                                       | Keyence                               | N/A                                                                 |
| 1200EX Transmission Electron Microscope                                       | JEOL                                  | N/A                                                                 |
| LSRFortessa SORP                                                              | BD Bioscience                         | N/A                                                                 |
| FACS Aria Fusion                                                              | BD Bioscience                         | N/A                                                                 |
| MagNA Lyser                                                                   | Roche                                 | N/A                                                                 |
| Odyssey Infrared Imager                                                       | Li-Cor                                | N/A                                                                 |
| Nanosight NS300                                                               | Malvern Instruments                   | N/A                                                                 |

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Information and requests for reagents and mice should be directed to the Lead Contact, Philipp Scherer ([Philipp.Scherer@UTSouthwestern.edu](mailto:Philipp.Scherer@UTSouthwestern.edu)).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Mouse Models

All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern (UTSW) Medical Center (Dallas, TX). The Cav1 gene was specifically ablated in mature adipocytes using the loxP system combined with the constitutively active adiponectin-cre (aCre). An inducible mouse model was also generated with a tetracycline response element (TRE)-driven cre recombinase (iCre). Specificity for the adipocyte in this model was accomplished by using the reverse tetracycline transactivator (rtTA) under the control of the adiponectin (APN) promoter ([Figure S1](#)).

To generate tissue-specific doxycycline-inducible Cav1-mSOG mice, the coding sequence for full length murine caveolin-1 was first cloned from murine subcutaneous adipose tissue cDNA; a Kozak sequence of 5'-GCCGCCACC-3' was placed in front of the caveolin-1 start codon. This cDNA was cloned into a pBAD vector containing sites for insertion of a C-terminal double miniSOG. After amplification, the Cav1-miniSOG fusion protein sequence was removed by NheI and XbaI and cloned into the "tight" pTRE-promoter vector in which we had previously placed a rabbit  $\beta$ -globin 3'UTR at the 3' end. Following linearization and purification, TRE-Cav1-miniSOG DNA was injected into C57Bl6/N embryos by the Transgenic Core at UT Southwestern Medical Center. Positive founder pups were screened for both tight repression at baseline and doxycycline inducibility in adipose tissue when crossed with the adiponectin-rtTA mouse line.

Generation of the inducible, plasma membrane-targeted halo mouse was accomplished using a pDisplay-Halo vector. HindIII and NotI were used to excise the IgK-HA-Halo-myc-PDGFR fragment, which was cloned into the TRE-promotor vector and processed for submission to the Transgenic Core as described above. Induction of gene expression in all inducible models was achieved by 600 mg/kg doxycycline in the diet for the indicated durations. Both control and transgenic mice received doxycycline. All mice used in this study were males.

In all cases where doxycycline was required to induce gene expression, it was supplied in the mouse diet. All mice received doxycycline including controls without the inducible transgenes (TRE-gene). Reference [Figures S1](#) and [S2](#) for mouse model breeding strategies and control mice genotypes.

### bEND.3 Cell Line

The immortalized mouse endothelial cell line bEND.3 was cultured in DMEM (4.5g/L glucose) supplemented with 10% FBS and penicillin-streptomycin. Documentation of these cells does not include information about their sex origin.

### Stromal Vascular Cells and Adipocyte Differentiation

SVF cells were isolated from male mice and cultured in DMEM/F12 media containing 10% FBS, glutamax, penicillin-streptomycin and gentamicin at 5% CO<sub>2</sub> in 37°C. For *in vitro* differentiation experiments SVF cells were allowed to grow to ~95% confluency. Adipogenesis was induced by culture media supplemented with 0.5 mM 3-isobutyl-1-methylxanthine, 1  $\mu$ M dexamethasone, 5  $\mu$ g ml<sup>-1</sup> Insulin and 1  $\mu$ M rosiglitazone for 48hr. Following the 48hr induction cells were cultured in media containing only 5  $\mu$ g ml<sup>-1</sup> Insulin.

### Primary Adipose Tissue Endothelial Cells

Endothelial cells from young male mice were plated on gelatin-coated plates (0.2% gelatin) and used for experiments at, or before passage 3. Endothelial cells were cultured in DMEM (4.5 g/L glucose) supplemented with 20% FBS, penicillin-streptomycin, and 100  $\mu$ g/ml ECGS. For all sEV-related experiments, exosome-free FBS was used.

## METHOD DETAILS

### Isolation of Primary Adipocytes, Stromal Vascular Cells and Endothelial Cells

The inguinal fat pads were dissected from male mice between the ages of 4-6 wk. Fat tissues were minced and digested for 1 hr at 37°C in buffer containing 100 mM HEPES, 1.5% BSA, 5 mM glucose, 1 mM calcium and 1mg/ml collagenase D. For adipocyte isolation, 2.4U/ml dispase II was included in the digestion buffer. Collagenase I was substituted for collagenase D for lung endothelial cell isolation. The dispersed tissue was then filtered through a 100  $\mu$ m cell strainer, and centrifuged at 600 g for 5 min at 4°C. The floating adipocytes were removed and used for biochemical analysis where indicated. The pelleted stromal vascular (SVF) cells were resuspended in culture media (DMEM/F12) and filtered through a 45  $\mu$ m cell strainer. Cells were centrifuged again as described above. The pelleted cells that were used for Flow Cytometry or FACS were incubated in Red Cell Lysis buffer and stained according to the Flow Cytometry section. Otherwise isolated SVF cells were either plated for adipocyte differentiation experiments or bead-sorted with anti-CD31-conjugated Dynabeads for endothelial cell isolation.

### Adipocyte Subcellular Fractionation

Mature adipocytes were isolated from the sWAT of 5 control and 8 aCre mice as described above. Adipocytes were pooled by respective genotype and homogenized in ice-cold buffer (10mM HEPES pH 7.4, 250mM sucrose, 10mM KCl, 2mM MgCl<sub>2</sub>, 1mM EDTA and 1mM EGTA) with a motor-driven Teflon/glass homogenizer. The nucleus and plasma membrane were pelleted at 720 g

for 5 min, and washed in homogenization buffer. The supernatant was poured through cheesecloth to separate the floating fat cake from the cleared homogenate. The supernatant was then centrifuged at 16 000xg for 20min to pellet the mitochondria and residual plasma membrane. The supernatant was centrifuged at 30 000xg to recover the microsomal fraction. The resulting supernatant was kept as the cytoplasmic fraction. Both the nuclear and mitochondrial pellets were resuspended in buffer containing 10 mM Tris pH 7.4, 1 mM EDTA and each was layered on a 1.12 M sucrose cushion with a 22G needle. The samples were then centrifuged at 100 000 x g for 60 min. The pellets contained the mitochondrial and nuclear fractions respectively, which were resuspended in an appropriate volume of 10 mM Tris pH 7.4, 1 mM EDTA supplemented with protease inhibitor cocktail. The supernatants from this spin contained floated plasma membranes. These plasma membrane bands were combined, diluted ~8 times the volume with homogenization buffer and spun 80 000xg to pellet the plasma membranes. The plasma membrane fraction was resuspended in the same buffer as the other fractions.

### Flow Cytometry

Flow cytometry experiments were carried out on a BD Bioscience LSRFortessa SORP flow cytometer (Children's Medical Center Research institute flow Core at UT Southwestern). Cells were sorted on a BD Bioscience FACS Aria Fusion (Children's Medical Center Research institute flow Core at UT Southwestern). Antibodies used for flow cytometry analysis can be found in the [Key Resources Table](#). For flow cytometry: samples of SVF cells from inguinal WAT depots (isolated as described in Isolation of Primary Adipocytes, Stromal Vascular Cells (SVF) and Endothelial Cells section) were first incubated at 4°C for 10 min in 10 uL of PBS containing 2% FBS with anti-mouse CD16/CD32 Fc Block (clone 2.4G2) (1:200). Cells were then incubated rocking at 4°C for 1 hour with primary antibodies (FITC anti-CD31 1:200, BV421 anti-CD45 1:200, PE or APC anti-CD140b (Pdgfb) 1:200, PE-CF594 anti F4/80 1:200, BB700 anti CD11b 1:200) and TMRDirect Halo Tag fluorescent ligand. The cells were then washed once with 200 uL PBS/2%FBS. Cells were centrifuged 5min at 4°C at 600 g and re-suspended in 200uL of PBS/2%FBS.

### Flow Cytometry Gating Strategy

Cells were initially selected by size, on the basis of forward scatter (FSC) and side scatter (SSC). Live cells were then gated on both SSC and FSCWidth singlets, ensuring that only individual cells were recorded. Unstained SVF cells isolated from WT mice were used to determine background fluorescence levels. The populations were gated as shown in [Figures S4](#) and [S5](#). Anti-F4/80 PE-CF594 and anti-CD11b BB700 antibodies were used to gate the macrophage population (F4/80+;CD11b+, Mac) and distinguish the non-macrophage population (F4/80-;CD11b-, No Mac). From F4/80+;CD11b+ population, cells containing anti-halo PE signal (Mac Halo) were gated. From the F4/80-;CD11b- population, cells were gated for 3 subpopulations: endothelial cells, hematopoietic and preadipocytes/mural cells. An anti-CD31 antibody was used to select for the endothelial cell population (CD31+). From this population, cells containing anti-halo PE signal (CD31 Halo) was gated. An anti-CD45 antibody to select the hematopoietic population (CD45+). From CD45+ population, cells containing anti-halo PE signal (CD45 Halo) was selected. Finally, the PDGFB+ preadipocyte cells were isolated from the CD31-;CD45- population using an anti-PDGFB antibody. Preadipocytes containing anti-halo PE were gated. The WT sample was used as a negative control to assure the specificity of the PE signal. All Flow Cytometry data was analyzed with FlowJo.

### Cell Labeling Techniques

Where indicated cells were labeled with 5  $\mu$ M FITC-PEG-Cholesterol (Nanocs, PG2-CSFC-3K). This dye was chosen because the cholesterol is naturally occurring, high-affinity membrane anchor that would likely be incorporated into EVs of all origins either by direct entry into plasma membrane-derived EVs or by entering the endocytic pathway with other components of the plasma membrane. PEGylation of cholesterol allowed for the compound to be easily solubilized in the aqueous media and excess dye easily washed away ([Figure S3](#)). Cells were then washed 5 times with PBS ([Figure S3](#)) and given fresh media for 2 d to allow for the accumulation of FITC-PEG-Cholesterol- labeled EVs in the media. Cell debris and large EVs were cleared from the media (as described in the [Isolation of sEVs From Cell Culture Conditioned Medium](#) section) and NTA analysis was used to determine the presence of FITC containing particles. SVF-differentiated adipocytes were then treated with the FITC-sEV containing conditioned media for 6 hr, washed, and analyzed for adipocyte-specific FITC signal indicative of adipocyte sEV uptake. Biotinylation of BSA was accomplished by the treatment of fatty acid- and endotoxin-free BSA with N-Hydroxysuccinimidobiotin per manufacturer's instruction (EZ-Link NHS-Biotin). Biotinylated BSA was dialyzed against sterile PBS to remove all unreacted reagent. Cells were treated with biotin-BSA as indicated.

### BSA-Alexa Fluor 488 and Biotin-BSA Uptake Assay

Primary ECs were grown to ~95% confluency on MatTek glass bottom microwell dishes. The cells were washed in PBS and serum-starved in HBSS for 3 hr. The cells were then treated with 0.1 mg/ml Alexa Fluor 488- conjugated BSA or 0.5 mg/ml biotinylated BSA in HBSS supplemented with 0.5 mg/ml unlabeled BSA for 30 min. Where indicated, cells were also treated with either insulin (5  $\mu$ g/ml), glucagon (20 nM) or GW4869 (10  $\mu$ M) during the BSA incubation period. Post-treatment ECs were washed thoroughly with PBS and either fixed in 4% paraformaldehyde for visualization of Alexa Fluor 488-BSA or given fresh media for assessment of biotin-BSA incorporation into sEVs. Cells were visualized by a Keyence BZ-X700 microscope. Fluorescence intensity was determined by ImageJ software.

### Transplant Studies

Male membrane halo mice were treated with doxycycline (600 mg/kg) in the diet for 2 wk to induce plasma membrane-targeted halo expression specifically in adipocytes. After the labeling period subcutaneous adipose tissue was excised from 6 wk old male MTMG mice, cut into ~100 mg pieces and surgically implanted into the dorsal subcutaneous adipose region of the halo mice. Recipient halo mice were maintained on doxycycline diet during the 3 wk period of implant integration, following which, the implants and surrounding inguinal adipose tissue were removed and processed for immunofluorescent staining.

### Immunofluorescence

Adipose tissue was harvested, fixed overnight in 10% PBS-buffered formalin, and washed with 50% ethanol. Tissues were embedded in paraffin blocks by the University of Texas Southwestern Medical Center Molecular Pathology Core and sectioned (5  $\mu$ m). For cells, following experimental procedures cells were washed with PBS and fixed for 20 min with 4% paraformaldehyde. For BSA-Alexa Fluor-488 uptake assays cells were imaged after fixation. For detection of cav1 and perilipin, cells were permeabilized post fixation with 0.1% Triton X-100. Primary antibodies used for both tissue sections and fixed cells were: perilipin, RFP, CD63, cav1, Halo, or affinity-purified anti-miniSOG (Covance). Fluorescence secondary antibodies used included: goat anti-rabbit Alexa Fluor 488, goat anti-guinea pig Alexa Fluor 647 and chicken anti-mouse Alexa Fluor 594. Where indicated, confocal images were acquired on a Zeiss LSM8800 Airyscan. Other fluorescence pictures were taken with a Keyence BZ-X700 microscope.

### Isolation of sEVs from Adipose Tissue

Mice to be used for sEV isolation were perfused through the heart at the left ventricle with PBS, 5 mM EDTA at a rate of 1 ml/min for 2 min to removed blood from the tissue. EDTA was washed out with a second perfusion of PBS alone. The inguinal fat pads from 5 mice were combined and digested as described above for the isolation of primary cells from adipose tissue. Special care was taken not to mince the tissue too finely as to avoid ruptured cells. Samples were diluted 1:1 in PBS and 2 mM EGTA to inhibit collagenase activity. Following centrifugation at 600 g for 5 min at room temperature the floating adipocytes were removed and discarded. The supernatant containing the sEVs was transferred into a glass 30 mL centrifuge tube and centrifuged at 1200 g at 4°C for 15 min. The supernatant was centrifuged again at 10 000 g at 4°C for 15 min. The resulting supernatant was then filtered through a 0.22  $\mu$ m syringe-driven filter to remove any contaminating microvesicles and any remaining cellular debris. Clarified samples were then concentrated to 250  $\mu$ l in 100 KD MWCO Amicon Ultra-15 centrifugal filter units and diluted to 10 mL in PBS containing 25 mM trehalose. Samples were then centrifuged in a fixed angle rotor at 100 000 g for 1.5 hr to pellet sEVs. The pellet was resuspended in PBS-trehalose buffer and centrifuged again at 100 000 g for 1.5 hr. The final pellet was resuspended in PBS and 2 mM trehalose.

### Isolation of sEVs From Cell Culture Conditioned Media

Endothelial cells were seeded equally between conditions and incubated in growth media containing exosome-free FBS for 48 hr. The media was recovered and centrifuged at 600 g at 4°C for 5 min to remove whole cells. The supernatant was then centrifuged at 1200 g for at 4°C for 15 min to remove cell debris and apoptotic bodies. The resulting supernatant was centrifuged at 10 000 g for 15 min at 4°C 30 min to remove IEVs. The final supernatant was centrifuged in a fixed angle rotor at 100 000 g for 1.5 hr to pellet sEVs. The pellet was resuspended in PBS and centrifuged again at 100 000 g for 1.5 hr.

### Nanoparticle Tracking Analysis

EV concentration and size distribution was determined by the dynamic light scattering technology of the Nanosight NS300. The NS300 was fitted with a flow-cell top plate, sample pump and 488 nm laser. The script was programed to take 5 videos for 30 s each for every sample. The final size and intensity values were averages between the 5 runs. For use of the Nanosight in fluorescence mode: the filter was engaged at the filter position for the blue laser (488 nm) to detect FITC signal. The thresholding pixels were optimized with the NTA 488 nm Fluorescence Standard Beads which contain fluorescent beads of known concentration and size distribution. Videos were acquired at the highest camera level under the same script conditions for unlabeled particles.

### Proteomics and Pathway Analysis

Samples were run into an SDS-PAGE gel. Proteins were excised from the gel and submitted to the UT Southwestern Proteomics Core. Samples were processed as previously described ([Kalantari et al., 2016](#)). Pathway Analysis was conducted with Reactome software.

### Sucrose Gradient Fractionation Analysis of EVs

Isolated EVs were analyzed by sucrose gradient centrifugation according to previously published protocol ([Chiou and Ansel, 2016](#)). Crude EV preparations were diluted in sucrose to a final concentration of 82%. The EVs were layered at the bottom of a sucrose gradient ranging from 82%–10% (1.002–1.34 g/ml calculated density). Samples were centrifuged at 100 000xg for 16 hr following which fractions were collected as follows: 10%–16% (F1), 22%–28% (F2), 34%–40% (F3), 46%–52% (F4), 58%–64% (F5), and 70%–82% (F6). The fractions were diluted 1:100 in PBS and centrifuged at 100 000xg for 1.5 hr to pellet any EVs. Pellets were resuspended in PBS and prepped for Western Blot. Samples were loaded into SDS-PAGE gels by volume normalization.

### Sphingolipid Quantification

Sphingolipids were quantified by LC/ESI/MS/MS using a Shimadzu Nexera X2 UHPLC system couple to a Shimadzu LCMS-8050 triple quadrupole mass spectrometer. Lipid species were identified and quantified based on their molecular mass and fragmentation patterns. All species were verified with lipid standards. Data were processed using the LabSolutions V 5.82 and LabSolutions Insight V 2.0 program packages.

### Western Blot

Protein was extracted from cells or tissue by homogenization in RIPA buffer supplemented with 1 mM EDTA, 20 mM NaF, 2 mM  $\text{Na}_3\text{VO}_4$ , and protease inhibitor cocktail. Proteins were separated by SDS-PAGE and transferred to either nitrocellulose or PVDF membrane. For western blots the gel lanes were loaded with equal protein: 20  $\mu\text{g}$ /well for adipocytes and SVF cells and 30  $\mu\text{g}$ /well for EV preparations unless indicated otherwise. The sucrose gradient experiments were analyzed by equal volume loading of SDS-PAGE gels. The blots were then incubated overnight at 4°C with primary antibodies. The Odyssey Infrared Imager was used to visualize western blots with Li-Cor IRdye secondary antibodies.

### Transmission Electron Microscopy


Electron microscopy samples were prepared by UT Southwestern Electron Microscopy Core. Briefly, sWAT pieces were fixed by perfusion with 4% paraformaldehyde and 1% glutaraldehyde in 0.1 mM sodium cacodylate buffer. The fixed tissue was then transferred to 2.5% glutaraldehyde in 0.1 mM sodium cacodylate buffer, post fixed in buffered 1% osmium tetroxide, en bloc stained in 4% uranyl acetate in 50% ethanol. Thin sections were cut on a Leica Ultracut UCT ultramicrotome and poststained with 2% uranyl acetate and lead citrate. Images were acquired on the JEOL 1200EX transmission electron microscope. For visualization of EVs by transmission electron microscopy (TEM), 5  $\mu\text{l}$  of the sEV sample was fixed overnight in 4% paraformaldehyde. 5  $\mu\text{l}$  of the fixed sEV solution was transferred to each Formvar-carbon coated (200 $\mu\text{m}$  Cu) electron microscopy grids. The grids were covered in incubated for 10 min. The grids were washed once with distilled water and stained with 2% uranyl acetate before visualization.

### qPCR

Isolated adipocytes and SVF were homogenized in TRIzol (Invitrogen) using a TissueLyser. RNA was isolated per the manufacturer's protocol. RNA quality and yield were determined by absorbance at 260nm, 280nm and 230nm. cDNA was prepared by reverse transcribing 1  $\mu\text{g}$  of RNA with the iScript cDNA Synthesis Kit. The results were calculated by the standard threshold cycle method and was used for normalization

### QUANTIFICATION AND STATISTICAL ANALYSIS

Data is presented as mean  $\pm$  SEM. \* $p < 0.05$ , \*\*  $p < 0.01$  and \*\*\* $p < 0.001$  by two-tailed Student's  $t$  test or one-way ANOVA. A  $p$  value  $< 0.05$  was determined to be statistically significant. All cell culture and qPCR data points were the average of technical duplicates. For primary cell culture experiments, the  $n$  value corresponds to a cell preparation from separate mice. For immortalized bEND.3 cell culture experiments the  $n$  value corresponds to an experiment conducted on separate passage number. For all mouse studies, the  $n$  value corresponds to individual mice of a given treatment. Data was analyzed used Prism GraphPad Software.




**Figure S1. Transgenic Cav1 Mouse Models, Related to STAR Methods**

(A) Constitutive, adipocyte-specific knockout of cav1 (aCre) was accomplished by a cross between mice homozygous for the floxed cav1 gene and mice that carry the adiponectin-cre transgene.

(B) The inducible, adipocyte-specific knockout of cav1 (iCre) was generated using a transgenic mouse carrying a tetracycline response element (TRE)-driven cre recombinase crossed with another that carried the reverse tetracycline transactivator (rtTA) under the control of the adiponectin promoter. All mice were homozygous for floxed cav1 genes. Upon doxycycline administration (supplied in the diet), rtTA is activated to bind the TRE and induce cre expression in an adipocyte-specific manner (TET-ON).

(C) Inducible cav1<sup>SOG</sup> overexpression specifically in endothelial cells was produced by crossing a mouse with a VE-cadherin promoter-driven tetracycline-controlled transactivator (TTA) and a mouse with the TRE-cav1<sup>SOG</sup> transgene. (TET-OFF). Mice were used as a constitutive overexpression model.




**Figure S2. Generation of Adipocyte-Specific Plasma Membrane-Targeted Halo-Tagged Mice, Related to STAR Methods**

(A) Mice were crossed that carried with adipocyte-specific reverse tetracycline transactivator (rtTA) and the tetracycline response element (TRE)-driven halo targeted to the plasma membrane (pDisplay vector). Administration of doxycycline results in rtTA binding to the TRE promoter and driving expression of the membrane-halo tag (TET-ON).


(B) Western blot analysis of the specificity of the membrane-halo expression over a collection of tissues.

(C) Immunofluorescent staining of the halo tag in sWAT sections.




**Figure S3. Wash Protocol For FITC-PEG-Cholesterol-Labeled ECs, Related to Figures 2E-2G**

Primary ECs were labeled with FITC-PEG-Cholesterol (incubation), followed by 8 washes (Wash 1-8) of equal volume with PBS. Each wash was sampled and analyzed for residual fluorescence.




**Figure S4. Flow Cytometry Gating Strategy for WT Mice, Related to Figure 3E and 3J**

Flow Cytometry gating strategy of Halo tag in sWAT cell populations: preadipocytes/mural cells (PDGFR $\beta$ ), hematopoietic cells (CD45), macrophages (Mac) and endothelial cells. See the [STAR Methods](#) for details.



**Figure S5. Flow Cytometry Gating Strategy for Adipocyte-Specific Plasma Membrane Halo Mice, Related to Figures 3E and 3J**

Flow Cytometry gating strategy of Halo tag in sWAT cell populations: preadipocytes/mural cells (PDGFR $\beta$ ), hematopoietic cells (CD45), macrophages (Mac) and endothelial cells. See the [STAR Methods](#) for details.



**Figure S6. Sucrose Gradient Analysis of Adipose Tissue IEVs, Related to Figure 4**

IEVs isolated from sWAT were separated on a sucrose gradient. Western blot analysis was used to determine the relative levels of (A) exosomal markers and (B) contamination markers among the fractions.